Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere? Sean G. KellyAmesika N. NyakuBabafemi O. Taiwo Current Opinion 17 February 2016 Pages: 523 - 531
Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection Denise C. HsuIrini Sereti Leading Article 25 February 2016 Pages: 533 - 549
The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions Paolo CuratoloMarit BjørnvoldBernard A. Zonnenberg Therapy in Practice 29 February 2016 Pages: 551 - 565
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent George G. ZhanelDoris CheungJames A. Karlowsky Review Article 10 February 2016 Pages: 567 - 588
Antipsychotic Management of Schizoaffective Disorder: A Review Jean-Pierre LindenmayerAmandeep Kaur Review Article 29 February 2016 Pages: 589 - 604
Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Gillian M. Keating Adis Drug Evaluation 16 March 2016 Pages: 605 - 615
Elbasvir/Grazoprevir: First Global Approval Gillian M. Keating AdisInsight Report 04 March 2016 Pages: 617 - 624
Comment on: “Therapies to Preserve β-Cell Function in Type 1 Diabetes” Devi Dayal Letter to the Editor 15 March 2016 Pages: 625 - 626
Author’s Reply to Dayal: “Therapies to Preserve β-Cell Function in Type 1 Diabetes” Johnny Ludvigsson Letter to the Editor 15 March 2016 Pages: 627 - 627